| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049041480 |
| P356 | DOI | 10.1007/S002130000532 |
| P698 | PubMed publication ID | 11057521 |
| P5875 | ResearchGate publication ID | 12268424 |
| P50 | author | Shitij Kapur | Q20713543 |
| P2093 | author name string | Houle S | |
| Wilson AA | |||
| Seeman P | |||
| Silvestri S | |||
| Seeman MV | |||
| Remington GJ | |||
| Negrete JC | |||
| Zipursky RB | |||
| Christensen BK | |||
| Shammi CM | |||
| P433 | issue | 2 | |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 174-180 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study | |
| P478 | volume | 152 |
| Q38708602 | A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia |
| Q90427479 | A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter |
| Q97092488 | A focused update on tardive dyskinesia |
| Q38111956 | A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder |
| Q38661176 | Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. |
| Q26773403 | Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia |
| Q28569752 | Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade |
| Q40898013 | Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial |
| Q38855787 | Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. |
| Q39664514 | Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y neuroblastoma cells |
| Q40136199 | Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions |
| Q44282697 | Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics |
| Q37218474 | Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition |
| Q30458391 | Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. |
| Q57460407 | Biased antagonism of CXCR4 avoids antagonist tolerance |
| Q46446461 | Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers |
| Q28484377 | Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response |
| Q35208019 | Calculating occupancy when one does not have baseline: a comparison of different options |
| Q45052993 | Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine |
| Q36518167 | Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability |
| Q37322237 | Classifying antipsychotic agents : need for new terminology |
| Q34391577 | Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders |
| Q43135422 | Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study |
| Q44574528 | D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder |
| Q42056580 | D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis |
| Q46439909 | D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats |
| Q46354616 | Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol |
| Q98627631 | Disentangling relapse and adherence in psychosis |
| Q33996824 | Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse |
| Q28249116 | Does nicotine affect D2 receptor upregulation? A case-control study |
| Q92549251 | Dopamine and glutamate in schizophrenia: biology, symptoms and treatment |
| Q45146910 | Dopamine modulates excitability of basolateral amygdala neurons in vitro |
| Q47618934 | Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice |
| Q37699366 | Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study |
| Q40385799 | Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate: a case report |
| Q84543334 | D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection |
| Q80278920 | Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study |
| Q38211233 | Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies |
| Q37672380 | Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys |
| Q46798703 | Effects of vitamin E supplementation on plasma membrane permeabilization and fluidization induced by chlorpromazine in the rat brain |
| Q46728122 | Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects |
| Q42970777 | Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra |
| Q43218202 | Frontal feedback-related potentials in nonhuman primates: modulation during learning and under haloperidol. |
| Q50578790 | G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. |
| Q35915318 | Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia |
| Q80577448 | Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia |
| Q36992322 | Glutamate and dopamine in schizophrenia: an update for the 21st century |
| Q64999981 | Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. |
| Q39066006 | Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (±)-α-lipoic acid in SH-SY5Y neuroblastoma cells |
| Q47556225 | Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? |
| Q34377871 | Is schizophrenia a dopamine supersensitivity psychotic reaction? |
| Q37451403 | Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials |
| Q44894528 | Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations |
| Q46789002 | Metoclopramide, an increasingly recognized cause of tardive dyskinesia |
| Q86572676 | MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348 |
| Q94603111 | Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed |
| Q38332389 | Movement disorders and psychosis, a complex marriage |
| Q51865932 | Movement disorders should be a criterion for schizophrenia in DSM-V. |
| Q50074889 | Neuronal traffic signals in tardive dyskinesia: not enough "stop" in the motor striatum |
| Q45369595 | Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function |
| Q27313333 | Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function |
| Q34432134 | Olanzapine: a review of its use in the treatment of bipolar I disorder |
| Q40058614 | On and Off switches in the brain |
| Q33938316 | Pre-operative evaluations for DBS in dystonia |
| Q41657879 | Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status |
| Q38219577 | Presynaptic dopaminergic function: implications for understanding treatment response in psychosis |
| Q37598278 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia |
| Q48228497 | Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats |
| Q49047575 | Psychopharmacology: A house divided |
| Q35847706 | Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone |
| Q39170484 | Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up |
| Q50908416 | Risperidone-to-methylphenidate switch reaction in children: three cases. |
| Q91861211 | State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia |
| Q36508056 | Tardive dyskinesia and essential fatty acids |
| Q34651191 | Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction |
| Q38032249 | Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis |
| Q38164868 | Tardive dyskinesia syndromes: current concepts. |
| Q28239223 | The case against antipsychotic drugs: a 50-year record of doing more harm than good |
| Q97556098 | The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus |
| Q37062793 | The nature of dopamine dysfunction in schizophrenia and what this means for treatment |
| Q51020963 | The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation. |
| Q37855779 | The role of antipsychotics in smoking and smoking cessation |
| Q35236574 | The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis. |
| Q57715315 | The use of healthy volunteers instead of patients to inform drug dosing studies: a [11C]raclopride PET study |
| Q34659357 | The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? |
| Q39084564 | Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation |
| Q37338151 | Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism |
| Q45778269 | Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study |
| Q36600801 | Treatment Response in First-episode Schizophrenia |
| Q52683873 | Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. |
| Q34338202 | Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs |
| Q40225855 | Untangling ligand induced activation and desensitization of G-protein-coupled receptors |
| Q58588172 | Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q39279185 | α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia |
Search more.